ALK-Abelló A/S provided earnings guidance for the full year 2023. As announced on 17 April, 2023, ALK confirms its full-year revenue and earnings outlook, albeit with changes in the anticipated product mix, where SCIT and SLIT-drops sales are now expected to exceed the original expectations, while tablet sales are now expected to grow by 9% to 14% (previously: up to 15%). Total revenue is still expected to grow by 7% to 11% organically in local currencies, corresponding to 8% to 12% growth, disregarding the one-year temporary mandatory rebate increase for prescription drugs in ALK's larger market, Germany.

The operating margin (EBIT) is still expected to increase on sales growth, efficiencies, economies of scale and lower R&D costs, despite tougher market conditions. The EBIT margin is still expected at 13% to 15%.